Back to top
more

Perrigo (PRGO)

(Delayed Data from NYSE)

$27.58 USD

27.58
3,889,579

-0.60 (-2.13%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $27.57 -0.01 (-0.04%) 6:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Perrigo's (PRGO) Q2 Earnings Misses by a Cent, Sales Beat

Perrigo (PRGO) delivers mixed second-quarter 2022 results. Higher demand for cough/cold products continues during the reported quarter. Unfavorable currency movements hurt sales and earnings.

Perrigo (PRGO) Lags Q2 Earnings Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of -2.27% and 5.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is ProShares S&P MidCap 400 Dividend Aristocrats ETF (REGL) a Strong ETF Right Now?

Smart Beta ETF report for REGL

QuidelOrtho (QDEL) Q2 Earnings Miss Estimates

QuidelOrtho (QDEL) delivered earnings and revenue surprises of -42.55% and 7.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AdaptHealth Corp. (AHCO) Surges 8.3%: Is This an Indication of Further Gains?

AdaptHealth Corp. (AHCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Perrigo (PRGO) to Report Q2 Earnings: What's in the Cards?

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Brainsway Ltd. Sponsored ADR (BWAY) Stock Jumps 9.4%: Will It Continue to Soar?

Brainsway Ltd. Sponsored ADR (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA

The FDA's potential approval of Perrigo (PRGO) unit, HRA Pharma's OTC birth control pills can make the drug the first of its kind to be made available without prescription in the United States.

Why Is Perrigo (PRGO) Up 13.4% Since Last Earnings Report?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs

Perrigo (PRGO) reports mixed first-quarter 2022 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Costs headwinds offset volume and price growth.

Perrigo (PRGO) Q1 Earnings Lag Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of -21.43% and 1.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Brookdale Senior Living (BKD) Reports Q1 Loss, Tops Revenue Estimates

Brookdale (BKD) delivered earnings and revenue surprises of -45.95% and 1.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Perrigo (PRGO) Q1 Earnings Expected to Decline

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Perrigo (PRGO) Up 0.9% Since Last Earnings Report?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Perrigo (PRGO) Q4 Earnings Beat as Cough & Cold Sales Recover

Perrigo (PRGO) reports encouraging fourth-quarter 2021 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Stock gains.

Perrigo (PRGO) Beats Q4 Earnings and Revenue Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of 7.14% and 0.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Hanger (HNGR) Q4 Earnings and Revenues Beat Estimates

Hanger (HNGR) delivered earnings and revenue surprises of 5.26% and 0.16%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug/Biotech Stocks' Q4 Earnings on Mar 1: PRGO, JAZZ & More

Let us look at five drug/biotech companies, PRGO, JAZZ, HZNP, SRPT and AXSM, which are gearing up for their earnings release.

Urmimala Biswas headshot

3 Medical Device Stocks Poised to Beat This Earnings Season

The Medical device companies' Q4 results are likely to reflect base business recovery on a year-over-year basis. Let's see how PRGO, COO and SGHT are poised ahead of their earnings releases.

Is a Beat Likely for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Are These Medical Stocks a Great Value Stocks Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

What Makes Perrigo (PRGO) a New Buy Stock

Perrigo (PRGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.